| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 14, 2023 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 9
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 3
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 8
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 254,275 | -- | -- |
| Oct 01, 2018 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 256,540 | -- | 256,540 |
| Apr 01, 2021 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.